Peritoneal Cancer Pipeline Insights | Clinical Trial Research Evaluation Report

New York, USA, June 13, 2022 (GLOBE NEWSWIRE) — Peritoneal Cancer Pipeline Insights | Clinical Trial Research Evaluation Report

The rising prevalence of Peritoneal Cancer has drawn the attention of pharmaceutical companies to research and develop potential treatments. Some of the major players include ImmunoGen, Merck & Co., Pfizer, Corcept therapeutics, Genmab/Seagen, Alkermes plc, and several others.

DelveInsight’s ‘Peritoneal Cancer Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Peritoneal Cancer therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the Peritoneal Cancer pipeline domain.

Key Takeaways from the Peritoneal Cancer Pipeline Report

• DelveInsight’s Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Peritoneal Cancer treatment. 
• The leading Peritoneal Cancer companies such as Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck & Co, AstraZeneca, Lee’s Pharmaceutical, Corcept Therapeutics, GlaxoSmithKline, Bristol-Myers Squibb, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology, Context Therapeutics, Astex Pharmaceuticals, APIM Therapeutics, Celsion, Regeneron Pharmaceuticals, Mucpharm Pty Ltd, Artios Pharma, Sumitomo Dainippon Pharma, OncoQuest Pharma, Genelux Corporation, Y-mAbs Therapeutics, PGEN Therapeutics, Jiangsu HengRui Medicine, Alkermes, Zenith Epigenetics, Sutro Biopharma, K-Group Beta, Bio-Path Holdings, Celldex Therapeutics, Rhizen Pharmaceuticals, Shattuck Labs, Inc., SELLAS Life Sciences Group, LIPAC oncology, Oncoinvent AS, Mereo Biopharma, Solasia Pharma, Mersana Therapeutics,  Zentalis Pharmaceuticals, Lumicell Inc., Avenge Bio and others are developing novel drug candidates to improve the Peritoneal Cancer treatment landscape.
• Key Peritoneal Cancer pipeline therapies in various stages of development include Nemvaleukin, olvimulogene nanivacirepvec, ZEN003694, 131 I-8H9, Dostarlimab, STRO-002, ZN-c3,  CDX-1140, TRK-950, RP12146, SL-172154, Galinpepimut S,AVB-001, MEK162, BP1001-A, Mirvetuximab Soravtansine, sodium selenite pentahydrate, Oregovomab, Trabectedin, Navicixizumab, Pembrolizumab, DCVAC/OvCa, DPX-Survivac, Adavosertib, Gimatecan, GEN-1, DSP-7888, Relacorilant, Topotecan, PF-06873600, Enzalutamide, REGN5668, Bevacizumab, Onapristone, Durvalumab, SG001, tisotumab vedotin, Guadecitabine, ATX-101, ART0380, and others.
• Enlivex has planned to initiate a Phase Ib trial evaluating Allocetra in combination with chemotherapy in solid peritoneal tumors in Q3 2022. The company evaluated preclinical studies in peritoneal cancer that shown a substantial survival benefit when Allocetra is combined with chimeric antigen receptor (CAR) T-cell therapy.
• In January 2022, Avenge Bio, announced the closing of its Series A financing of $45 Million. The round of financing was co-led by Perceptive Xontogeny Venture Fund and CAM Capital, with participation from seed investor Longitude Capital and new investors Rock Springs Capital and Pappas Capital. Proceeds from the Series A financing will be used to advance Avenge Bio’s lead program, AVB-001, through the filing of an Investigational New Drug (IND) application and into the clinic for the treatment of metastatic peritoneal cancers, with a primary focus on recurrent and refractory ovarian cancer. 
• GRN-300 (previously ARN3261) is an orally bioavailable first-in-class novel, small molecule, dual inhibitor of the salt-inducible kinases 2 and 3 (SIK2, SIK3). A Phase I os being conducted to evaluate the safety, pharmacokinetics and efficacy of GRN-300 alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers.
• In August 2021, the FDA granted a fast track designation to STRO-002 for use in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received 1 to 3 lines of systemic therapy.
• In December 2021, Ascentage Pharma entered into a clinical collaboration with Clover Biopharmaceuticals, to evaluate Ascentage Pharma’s APG-1387, a second mitochondria-derived activator of caspase (SMAC)-mimetic/inhibitor of apoptosis proteins (IAP) antagonist, in combination with Clover’s SCB-313, a recombinant human TRAIL-trimer fusion protein, in a Phase Ib/II study in patients with advanced peritoneal carcinomatosis.

Request a sample and discover the recent breakthroughs and advances in treating Peritoneal Cancer @ Peritoneal Cancer Pipeline Outlook

The Peritoneal Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Peritoneal Cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Peritoneal Cancer pipeline landscape.

Peritoneal Cancer Overview

Peritoneal Cancer is a rare type of cancer that originates in the peritoneum, which is a thin, fragile fabric that borders the interior wall of the abdomen, covers the uterus, and extends over the bladder and rectum. Peritoneal cancer appears and acts similarly to ovarian cancer; however, the ovaries are only marginally involved. After having their ovaries removed previously, women who acquire ovarian cancer are most likely suffering from peritoneal cancer. The Peritoneal Cancer causes are unknown. The 5-year Peritoneal Cancer survival rate for women with all types of the ovarian, fallopian tube, and peritoneal cancers is 47%. 

Peritoneal cancer, like ovarian cancer, can be challenging to detect in its early stages. This is because Peritoneal Cancer symptoms are hazy and difficult to nail down. When apparent signs do appear, the disease has frequently advanced. The symptoms of Peritoneal Cancer will then resemble those of ovarian cancer. Many of these symptoms are caused by fluid accumulation (ascites) in the abdomen. The common Peritoneal Cancer symptoms include nausea, constipation, frequent urination, rectal bleeding, bloating or cramps, and others.

Peritoneal Cancer diagnosis is difficult. Imaging (such as CT or MRI scans), ascitic fluid needle drainage for analysis, keyhole surgery, or a combination of these procedures may be necessary to confirm the Peritoneal Cancer diagnosis. Peritoneal cancer treatment is determined by the Peritoneal Cancer stages, where the main tumor began, how far it has progressed, and the patient’s general condition. Surgery, chemotherapy, radiation, and targeted therapy are all Peritoneal Cancer treatment options.

Find out more about Peritoneal Cancer treatment @ Peritoneal Cancer Therapy

A snapshot of the Peritoneal Cancer Pipeline Drugs mentioned in the report:

Learn more about the novel and emerging Peritoneal Cancer pipeline therapies @ Peritoneal Cancer Clinical Trials

Peritoneal Cancer Therapeutics Assessment

The Peritoneal Cancer Pipeline report proffers an integral view of the Peritoneal Canceremerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Scope of the Peritoneal Cancer Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
• Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
• Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Mitosis inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Programmed cell death-1 receptor antagonists, Immunostimulants, Cyclin-dependent kinase inhibitors, Antibody-dependent cell cytotoxicity, WEE1 protein inhibitors, T lymphocyte stimulants
• Key Peritoneal Cancer Companies: Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck & Co, AstraZeneca, Lee’s Pharmaceutical, Corcept Therapeutics, GlaxoSmithKline, Bristol-Myers Squibb, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology, Context Therapeutics, Astex Pharmaceuticals, APIM Therapeutics, Celsion, Regeneron Pharmaceuticals, Mucpharm Pty Ltd, Artios Pharma, Sumitomo Dainippon Pharma, OncoQuest Pharma, Genelux Corporation, Y-mAbs Therapeutics, PGEN Therapeutics, Jiangsu HengRui Medicine, Alkermes, Zenith Epigenetics, Sutro Biopharma, K-Group Beta, Bio-Path Holdings, Celldex Therapeutics, Rhizen Pharmaceuticals, Shattuck Labs, Inc., SELLAS Life Sciences Group, LIPAC oncology, Oncoinvent AS, Mereo Biopharma, Solasia Pharma, Mersana Therapeutics,  Zentalis Pharmaceuticals, Lumicell Inc., Avenge Bio and others.
• Key Peritoneal Cancer Pipeline Therapies: Nemvaleukin, olvimulogene nanivacirepvec, ZEN003694, 131 I-8H9, Dostarlimab, STRO-002, ZN-c3,  CDX-1140, TRK-950, RP12146, SL-172154, Galinpepimut S,AVB-001, MEK162, BP1001-A, Mirvetuximab Soravtansine, sodium selenite pentahydrate, Oregovomab, Navicixizumab, Pembrolizumab, DCVAC/OvCa, DPX-Survivac, Adavosertib, Gimatecan, GEN-1, DSP-7888, Relacorilant, Topotecan, PF-06873600, Enzalutamide, REGN5668, Bevacizumab, Onapristone, Durvalumab, SG001, tisotumab vedotin, Guadecitabine, ATX-101, ART0380 and others.

Dive deep into rich insights into new Peritoneal Cancer drugs, visit @ Peritoneal Cancer Treatment 

Table of Contents

For further information on the Peritoneal Cancer pipeline therapeutics, reach out @ Peritoneal Cancer Drugs

Related Reports

Peritoneal Dialysis Equipment Market

Peritoneal Dialysis Equipment Market Insights, Competitive Landscape, and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Peritoneal Dialysis Equipment companies including Baxter, Fresenius Medical Care AG & Co. KGaA, Terumo Corporation, Medtronic, among others.

Peritoneal Dialysis Equipment Pipeline

Peritoneal Dialysis Equipment Pipeline Insight and Competitive Landscape, 2022 report provides comprehensive insights about the pipeline landscape, pipeline devices profiles, including clinical and non-clinical stage products, and the key Peritoneal Dialysis Equipment companies including Honeywell International, Fresenius Medical Care AG & Co. KGaA, Braun Melsungen AG, among others.

Peritoneal Carcinomatosis Epidemiology Forecast

Peritoneal Carcinomatosis Epidemiology Forecast–2032 report delivers an in-depth understanding of the Peritoneal Carcinomatosis, historical and forecasted epidemiology as well as the Peritoneal Carcinomatosis epidemiology trends.

Peritoneal Carcinomatosis Market 

Peritoneal Carcinomatosis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Peritoneal Carcinomatosis companies including Johns Hopkins University, Carlos Chan, University of Iowa, among others.

Peritoneal Carcinomatosis Pipeline

Peritoneal Carcinomatosis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Peritoneal Carcinomatosis companies including Johns Hopkins University, Carlos Chan, University of Iowa, among others.

Advanced Ovarian Cancer Pipeline

Advanced Ovarian Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Advanced Ovarian Cancer companies including ImmunoGen, OncoQuest, Lee’s Pharmaceutical, among others.
Other Trending Reports

Pediatric Growth Hormone Deficiency Market | Non-Cystic Fibrosis Bronchiectasis Market | X-Linked Retinitis Pigmentosa Market | Otitis Media Market | Central Retinal Vein Occlusion Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect With Us at LinkedIn Contact Us